On Jul 25, 6:54 pm, Steve Jordan <mycrofts...@cox.net> wrote:
> From Medscape, a review of PCa tx news from the recent ASCO (American
> Society for Clinical Oncology) meeting:
>
> http://www.medscape.com/viewarticle/559836?src=mp
I finally got around to reading this. If I read it correctly,
some interesting conclusions were:
1. Longer hormone therapy (3 years) after radiation extends life
for more patients than does shorter therapy (6 months).
2. Patients on long term hormone therapy did not have worse
"global health" than patients on short term therapy. My
interpretation: Hormone therapy will _not_ kill you or make
you sick.
3. Intermittent therapy did at least as well as non-intermittent
therapy. The numbers were actually significantly better for
intermittent therapy, but the study population size was too
small to conclude too much from it.
4. Satraplatin, a new chemotherapy agent, extended survival for a
significant number of patients who had become resistant to
docetaxel.
5. A couple of new, novel, drugs (irofulven and abiraterone)
appeared to extend life in HRPC.
6. A new type of whole body radiation appears to be useful both
in palliating bone pain and in extending life for men with
metastatic disease. Radioactive chemicals are administered
that tend to concentrate in bones and deliver the radiation
there.
If someone reads the abstract and disagrees with my summary,
please correct me.
Alan
The Latest on Tx 
Linear Mode
